Dedifferentiated melanoma is a particular form of malignant melanoma with a progressive worsening of the patient's clinical outcome. It is well known that melanoma can assume different histo-morphological patterns, to which specific genetic signatures correspond, sometimes but not always. In this review we address the diagnostic difficulties in correctly recognizing this entity, discuss the major differential diagnoses of interest to the dermatopathologist, and conduct a review of the literature with particular attention and emphasis on the latest molecular discoveries regarding the dedifferentiation/undifferentiation mechanism and more advanced therapeutic approaches.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8544555 | PMC |
| http://dx.doi.org/10.3390/dermatopathology8040051 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Steatohepatitis-induced vascular niche alterations promote melanoma metastasis.
Cancer Metab
January 2025
Department of Dermatology, Venereology and Allergology, University Medical Center and Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, Mannheim, 68167, Germany.
Background: In malignant melanoma, liver metastases significantly reduce survival, even despite highly effective new therapies. Given the increase in metabolic liver diseases such as metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), this study investigated the impact of liver sinusoidal endothelial cell (LSEC)-specific alterations in MASLD/MASH on hepatic melanoma metastasis.
Methods: Mice were fed a choline-deficient L-amino acid-defined (CDAA) diet for ten weeks to induce MASH-associated liver fibrosis, or a CDAA diet or a high fat diet (HFD) for shorter periods of time to induce early steatosis-associated alterations.
The Diagnostic Utility of PRAME in Primary Cutaneous Dedifferentiated and Transdifferentiated Melanomas.
J Cutan Pathol
January 2025
Department of Anatomical Pathology, Dorevitch Pathology, Heidelberg, Victoria, Australia.
Melanomas show a wide spectrum of clinical, morphological, immunohistochemical, and molecular features, which can impact treatment and prognosis. Dedifferentiated and transdifferentiated melanomas (DTM) are defined as melanomas which have lost conventional melanocytic morphologic and immunohistochemical features, showing sarcomatous morphology and/or immunohistochemical staining of other cell lineages, and as such, can be mistaken for other entities such as collision tumors and undifferentiated spindle cell tumors. In this series, we highlight the utility of preferentially expressed antigen in melanomas (PRAME) in diagnosing undifferentiated/dedifferentiated melanomas.
View Article and Find Full Text PDFDifferentiation status determines the effects of IFNγ on the expression of PD-L1 and immunomodulatory genes in melanoma.
Cell Commun Signal
December 2024
Department of Biomedical Science, Faculty of Medicine, BioMedical Center, University of Iceland, Reykjavík, Iceland.
Background: Melanoma cells frequently dedifferentiate in response to inflammation which can increase responses to certain cytokines. Interferon-γ (IFNγ) is an integral part of the anti-tumor immune response and can directly induce both differentiational changes and expression of immunosuppressive proteins in melanoma cells. How the differentiation status of melanoma cells affects IFNγ responses remains unclear.
View Article and Find Full Text PDFArticle Synopsis
- Liposarcomas are the most common type of soft tissue sarcoma, primarily found in deep tissues and the retroperitoneum.
- They include various classifications such as atypical lipomatous tumors, well-differentiated liposarcoma (WDL), dedifferentiated liposarcoma (DDL), myxoid liposarcoma, and pleomorphic liposarcoma.
- DDL is especially common in the retroperitoneum and can have both well-differentiated lipomatous and dedifferentiated components, sometimes resembling other aggressive tumors, and can even differentiate into several other cancer types or form bone tissue.
Mitochondrial signatures shape phenotype switching and apoptosis in response to PLK1 inhibitors.
Life Sci Alliance
March 2025
Faculté de Pharmacie, Université de Montréal, Montréal, Canada
Article Synopsis
- PLK1 inhibitors are being researched as potential cancer treatments, but challenges like low effectiveness and tumor relapse in clinical settings hinder their success.
- Mitochondrial protein signatures in melanoma cells affect how these cells respond to PLK1 inhibitors, with resistant cells becoming more inflammatory while sensitive cells undergo cell death.
- The study suggests that targeting mitochondrial functions and understanding the role of PLK1 can enhance treatment responses and lead to better therapeutic strategies.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!